Does Peter Attia recommend DHEA?
Peter Attia recommends DHEA in some contexts, but has also raised cautions.
Published research rates it weak evidence. Of Peter Attia's 73 tracked claims, 23 are supported or partially supported by studies on PubMed.
Evidence last reviewed May 2026
Peter Attia on DHEA — 73 claims
“I do measure DHEA-S — the sulfated form — in patients over 50.”
In his practice, Attia measures DHEA-S — the sulfated form — in patients over 50.
The published literature consistently establishes DHEA-S as a clinically meaningful biomarker, particularly in the context of aging. The adrenopause review (PMID: 18839621) specifically documents the…
“I do measure DHEA-S — the sulfated form — in patients over 50.”
In his practice, Attia measures DHEA-S — the sulfated form — in patients over 50.
The expert's claim is a clinical practice recommendation about measuring DHEA-S levels in patients over 50, which is a diagnostic/monitoring approach rather than a therapeutic intervention. None of th…
“If levels are very low, I'll sometimes trial DHEA at 25 to 50 milligrams per day, monitoring downstream hormones, PSA in men, and lipid panels.”
If DHEA-S levels are very low in patients over 50, Attia will sometimes trial DHEA at 25 to 50 milligrams per day, monitoring downstream hormones, PSA in men, and lipid panels.
None of the 10 provided studies directly evaluate the clinical protocol described by Attia — specifically, trialing DHEA at 25–50 mg/day in individuals over 50 with low DHEA-S levels while monitoring…
“I do measure DHEA-S — the sulfated form — in patients over 50.”
In his practice, Attia measures DHEA-S — the sulfated form — in patients over 50.
The expert's claim concerns a clinical practice recommendation — measuring DHEA-S (the sulfated form) in patients over 50 — which is a diagnostic/monitoring practice rather than a supplementation or i…
“If levels are very low, I'll sometimes trial DHEA at 25 to 50 milligrams per day, monitoring downstream hormones, PSA in men, and lipid panels.”
If DHEA-S levels are very low in patients over 50, Attia will sometimes trial DHEA at 25 to 50 milligrams per day, monitoring downstream hormones, PSA in men, and lipid panels.
The expert's clinical approach of trialing DHEA at 25–50 mg/day in patients over 50 with low DHEA-S levels is broadly consistent with the literature on adrenopause (PMID 18839621) and DHEA supplementa…
“I do measure DHEA-S — the sulfated form — in patients over 50.”
In his practice, Attia measures DHEA-S — the sulfated form — in patients over 50.
The expert's claim concerns a clinical measurement practice — specifically monitoring DHEA-S (the sulfated form) in patients over 50 — rather than a supplementation or intervention claim. None of the…
“If levels are very low, I'll sometimes trial DHEA at 25 to 50 milligrams per day, monitoring downstream hormones, PSA in men, and lipid panels.”
If DHEA-S levels are very low in patients over 50, Attia will sometimes trial DHEA at 25 to 50 milligrams per day, monitoring downstream hormones, PSA in men, and lipid panels.
The expert's practice of trialing DHEA at 25–50 mg/day for low DHEA-S levels in older adults aligns with the general clinical reasoning supported by several of the listed studies. The meta-analysis (P…
“I do measure DHEA-S — the sulfated form — in patients over 50.”
In his practice, Attia measures DHEA-S — the sulfated form — in patients over 50.
The expert's claim pertains to a clinical measurement practice — specifically measuring DHEA-S in patients over 50 — which is a standard diagnostic/monitoring decision rather than a supplement or inte…
“If levels are very low, I'll sometimes trial DHEA at 25 to 50 milligrams per day, monitoring downstream hormones, PSA in men, and lipid panels.”
If DHEA-S levels are very low in patients over 50, Attia will sometimes trial DHEA at 25 to 50 milligrams per day, monitoring downstream hormones, PSA in men, and lipid panels.
None of the provided studies directly examine the clinical practice of trialing DHEA at 25–50 mg/day in adults over 50 with low DHEA-S, nor do they assess the monitoring protocol Attia describes (down…
“If levels are very low, I'll sometimes trial DHEA at 25 to 50 milligrams per day, monitoring downstream hormones, PSA in men, and lipid panels.”
If DHEA-S levels are very low in patients over 50, Attia will sometimes trial DHEA at 25 to 50 milligrams per day, monitoring downstream hormones, PSA in men, and lipid panels.
The literature supports the general rationale for DHEA supplementation in individuals with low DHEA-S levels, particularly in the context of adrenopause (PMID 18839621) and adrenal insufficiency (PMID…
“I do measure DHEA-S — the sulfated form — in patients over 50. If levels are very low, I'll sometimes trial DHEA at 25 to 50 milligrams per day, monitoring downstream hormones, PSA in men, and lipid panels.”
In his practice, Attia measures DHEA-S in patients over 50, and if levels are very low, he will sometimes trial DHEA at 25 to 50 milligrams per day while monitoring downstream hormones, PSA in men, and lipid panels.
The practice of measuring DHEA-S and supplementing when low is grounded in established physiology. Multiple reviews (PMIDs 36121077, 30029723, 18839621) confirm DHEA-S declines with age ('adrenopause'…
“I do measure DHEA-S — the sulfated form — in patients over 50. If levels are very low, I'll sometimes trial DHEA at 25 to 50 milligrams per day, monitoring downstream hormones, PSA in men, and lipid panels.”
Attia measures DHEA-S in patients over 50 and, if levels are very low, may trial DHEA at 25 to 50 milligrams per day while monitoring downstream hormones, PSA in men, and lipid panels.
The practice of measuring DHEA-S and supplementing in older individuals with low levels is grounded in the well-documented decline of DHEA/DHEA-S with aging (PMID: 18839621) and is consistent with the…
“Epidemiological studies show that higher DHEA levels correlate with lower cardiovascular risk, less abdominal obesity, and better cognitive performance.”
Epidemiological studies show that higher DHEA levels correlate with lower cardiovascular risk, less abdominal obesity, and better cognitive performance.
None of the 10 retrieved studies directly address the expert's claim about DHEA levels correlating with cardiovascular risk, abdominal obesity, or cognitive performance in epidemiological research. Th…
“Epidemiological studies show that higher DHEA levels correlate with lower cardiovascular risk, less abdominal obesity, and better cognitive performance.”
Epidemiological studies show that higher DHEA levels correlate with lower cardiovascular risk, less abdominal obesity, and better cognitive performance.
The expert's claim specifically concerns epidemiological correlations between DHEA levels and cardiovascular risk, abdominal obesity, and cognitive performance. None of the 10 provided studies directl…
“Etienne-Emile Baulieu's DHEA-age trial showed modest improvements in bone density, skin quality, and libido in older adults but little effect on the primary outcomes.”
Baulieu's DHEA-age trial showed modest improvements in bone density, skin quality, and libido in older adults but little effect on primary outcomes.
The expert's claim specifically references the 'Baulieu DHEA-age trial' (also known as the DHEAge study), a well-known RCT published around 2000 by Etienne-Emile Baulieu. However, none of the 20 provi…
“More recent work suggests the effects may be more pronounced in women than men and in those with the lowest baseline levels.”
More recent research suggests DHEA's effects may be more pronounced in women than men and in those with the lowest baseline levels.
None of the 10 retrieved studies directly address Peter Attia's specific claim that DHEA's effects are more pronounced in women than men and in those with the lowest baseline levels. The most relevant…
“Etienne-Emile Baulieu's DHEA-age trial showed modest improvements in bone density, skin quality, and libido in older adults but little effect on the primary outcomes.”
The DHEA-age trial by Baulieu showed modest improvements in bone density, skin quality, and libido in older adults but little effect on the primary outcomes.
None of the 10 provided studies correspond to the DHEA-AGE trial by Baulieu et al., which is the specific RCT referenced in the expert's claim. The provided literature includes general DHEA reviews (P…
“Epidemiological studies show that higher DHEA levels correlate with lower cardiovascular risk, less abdominal obesity, and better cognitive performance.”
Epidemiological studies show that higher DHEA levels correlate with lower cardiovascular risk, less abdominal obesity, and better cognitive performance.
None of the 10 retrieved studies directly address the epidemiological associations between DHEA levels and cardiovascular risk, abdominal obesity, or cognitive performance. The most relevant paper (PM…
“Etienne-Emile Baulieu's DHEA-age trial showed modest improvements in bone density, skin quality, and libido in older adults but little effect on the primary outcomes.”
The DHEA-age trial by Baulieu showed modest improvements in bone density, skin quality, and libido in older adults but little effect on the primary outcomes.
None of the 10 provided studies correspond to the specific DHEAge trial by Baulieu et al. that Attia references. The retrieved literature includes general reviews on DHEA pharmacology (PMID 36121077),…
“More recent work suggests the effects may be more pronounced in women than men and in those with the lowest baseline levels.”
More recent research suggests DHEA's effects may be more pronounced in women than men and in those with the lowest baseline levels.
None of the 10 provided studies directly address the claim that DHEA's effects are more pronounced in women than men or in those with the lowest baseline levels. While PMID 36121077 is a review on DHE…
Other supplements Peter Attia discusses
Claims are extracted from publicly available podcasts and videos, attributed to their source, and compared against PubMed research. This is educational information only — consult a healthcare provider before starting any supplement.
Back to Peter Attia